WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $1.00. The company’s shares closed yesterday at ...

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...

Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS ...

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, ...

The EIT Community will be hosting the INNOVEIT Conference which will feature industry leaders like Inga Grieger, Katarzyna ...

On Thursday, Prelude Therapeutics Inc (PRLD) stock saw a decline, ending the day at $1.2 which represents a decrease of $-0.12 or -9.09% from the prior close of $1.32. The stock opened at $1.31 and ...

From St Thomas Church, Fifth Avenue, New York, on the eve of American Thanksgiving, with music by Hancock, Sebastian Forbes, ...

The financing will allow the firm to further develop its AI platform, develop drugs in best responders, and acquire new pipeline candidates.

The London jobs market is in worse shape than elsewhere in the country, with a new survey showing a marked drop in the pace ...

The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a ...

A Somerset maritime surveillance company has secured a £31m finance package from one of its existing shareholders in the US.